Skip to main content

Table 1 Baseline characteristics of the patients

From: Tyrosine-kinase inhibitor combined with iodine-125 seed brachytherapy for hepatocellular carcinoma refractory to transarterial chemoembolization: a propensity-matched study

Characteristic

Total cohort

 

Matched cohort

TKI-I group

(n = 68)

TKI group

(n = 64)

P

 

TKI-I group

(n = 48)

TKI group

(n = 48)

P

Sex

       

  Male

58 (85.3)

57 (89.1)

0.518

 

40 (83.3)

44 (91.7)

0.217

  Female

10 (14.7)

7 (10.9)

 

8 (16.7)

4 (8.3)

Age (years)

55.0 (29.0–75.0)

58.5 (28.0–75.0)

0.398

 

57.5 (35.0–75.0)

60.0 (28.0–75.0)

0.538

  < 60

42 (61.8)

32 (50.0)

0.173

 

25 (52.1)

23 (47.9)

0.683

  ≥ 60

26 (38.2)

32 (50.0)

 

23 (47.9)

25 (52.1)

ECOG PS

       

  1

22 (32.4)

27 (42.2)

0.242

 

15 (31.3)

15 (31.3)

> 0.999

  0

46 (67.6)

37 (57.8)

 

33 (68.8)

33 (68.8)

HBsAg

       

  Positive

56 (82.4)

58 (90.6)

0.166

 

40 (83.3)

44 (91.7)

0.217

  Negative

12 (17.6)

6 (9.4)

 

8 (16.7)

4 (8.3)

Child-Pugh class

       

  B

5 (7.4)

13 (20.3)

0.030

 

5 (10.4)

3 (6.3)

0.712

  A

63 (92.6)

51 (79.7)

 

43 (89.6)

45 (93.8)

AFP (µg/L)

209.1 (1.5-172903.5)

201.7 (1.3-800000.0)

0.623

 

276.2 (1.8-172903.5)

167.9 (1.3-800000.0)

0.758

  ≥ 200

35 (51.5)

32 (50.0)

0.866

 

27 (56.3)

23 (47.9)

0.414

  < 200

33 (48.5)

32 (50.0)

 

21 (43.8)

25 (52.1)

Number of tumors*

2 (1–10)

3 (1–10)

0.017

 

2 (1–10)

3 (1–10)

0.129

  > 3

17 (25.0)

28 (43.8)

0.023

 

14 (29.2)

21 (43.8)

0.138

  ≤ 3

51 (75.0)

36 (56.3)

 

34 (70.8)

27 (56.3)

Tumor distribution

       

  Bilobar

31 (45.6)

43 (67.2)

0.012

 

25 (52.1)

30 (62.5)

0.302

  Unilobar

37 (54.4)

21 (32.8)

 

23 (47.9)

18 (37.5)

Largest tumor size (cm)

7.9 (3.0-20.2)

8.2 (3.0-19.8)

0.340

 

8.3 (3.0-20.2)

8.9 (3.0-19.1)

0.373

  > 7.0

42 (61.8)

39 (60.9)

0.922

 

30 (62.5)

32 (66.7)

0.670

  ≤ 7.0

26 (38.2)

25 (39.1)

 

18 (37.5)

16 (33.3)

Macrovascular invasion

       

  Yes

55 (80.9)

48 (75.0)

0.415

 

36 (75.0)

40 (83.3)

0.315

  No

13 (19.1)

16 (25.0)

 

12 (25.0)

8 (16.7)

TKI

       

  Sorafenib

29 (42.6)

26 (40.6)

0.814

 

22 (45.8)

22 (45.8)

> 0.999

  Lenvatinib

39 (57.4)

38 (59.4)

 

26 (54.2)

26 (54.2)

Number of previous TACE

3 (2–11)

3 (2–9)

0.519

 

3 (2–7)

3 (2–9)

0.817

  2

23 (33.8)

26 (40.6)

0.419

 

16 (33.3)

20 (41.7)

0.399

  > 2

45 (66.2)

38 (59.4)

 

32 (66.7)

28 (58.3)

TACE technique

       

  D-TACE

28 (41.2)

28 (43.8)

0.765

 

22 (45.8)

24 (50.0)

0.683

  cTACE

40 (58.8)

36 (56.3)

 

26 (54.2)

24 (50.0)

  1. Data were presented as n (%) or median (range). *Six and 7 patients in TKI-I group and TKI group, respectively, in the total cohort, and 4 patients each in TKI-I group and TKI group in the matched cohort had more than 10 intrahepatic tumors, and the number of tumors was counted as 10. PSM propensity score matching, TKI-I tyrosine kinase inhibitor combined with iodine-125 seed brachytherapy, TKI tyrosine kinase inhibitor, ECOG PS Eastern Cooperative Oncology Group Performance Status, HBsAg hepatitis B surface antigen, AFP α-fetoprotein, TACE transarterial chemoembolization, D-TACE drug-eluting bead transarterial chemoembolization, cTACE conventional transarterial chemoembolization
Back to article page

Cancer Imaging

ISSN: 1470-7330

Contact us